Global Prenatal Testing & Newborn Screening Market

Non-invasive prenatal testing is a test in which blood from the mother is drawn and tested for possible abnormalities in the patient. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects, in fetuses in the first trimester of pregnancy. The non-invasive prenatal testing market consists of sales of non-invasive prenatal testing kits, instruments, and related services. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects, in fetuses in the first trimester of pregnancy. Non-invasive prenatal testing includes ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, and biochemical screening tests. The main types of non-invasive prenatal testing are consumables, and instruments. Consumables are products that are used up or depleted throughout their use. The various instrument used are NGS systems, PCR instruments, microarrays, ultrasound devices, and others (centrifuges, UV systems, incubators, microscopes) and the different consumables include assay kits and reagents, disposables. The applications involve trisomy, microdeletion, genetics, Rh factor that are used by hospitals and diagnostic labs. The non-invasive prenatal testing market research report is one of a series of new reports from The Business Research Company that provides non-invasive prenatal testing market statistics, including non-invasive prenatal testing industry global market size, regional shares, competitors with a non-invasive prenatal testing market share, detailed non-invasive prenatal testing market segments, market trends and opportunities, and any further data you may need to thrive in the non-invasive prenatal testing industry. This non-invasive prenatal testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global non-invasive prenatal testing market will grow from $4.21 billion in 2022 to $4.84 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global non-invasive prenatal testing market is expected to grow to $8.36 billion in 2027 at a CAGR of 14.7%. High incidence rate of Down syndrome is one major factor driving non-invasive prenatal testing (NIPT) market with increase in average maternal age which has led to a concern on the safety about the growth of the fetus. Down syndrome is a chromosomal condition that occurs when an error in cell division results in an extra chromosome 21 and can affect the fetus cognitive ability and physical growth. The NIPT screening tests do not harm the mother or baby, carries no risk of miscarriage as they are non-invasive, and can detect more than 99% of cases of Down syndrome. According to National Down Syndrome Society and Centres for Disease control and Prevention, in the USA, 1 in every 700 babies are born with Down syndrome and 80% of children with Down syndrome are born to older mothers. The increased risk of having babies with Down syndrome among older women drives the non-invasive prenatal testing market. The ethical hurdles in the non-invasive prenatal testing (NIPT) market have led to a range of ethical issues in terms of sex selection or aborting babies with chromosomal abnormality. Determining the sex of the fetus or knowing if the baby has an abnormality at an earlier stage led to abortions and resulted as an ethical issue which further led to strict regulations on using such devices. According to the official statistics provided by the UK government, a record 214,869 abortions were performed in the Englan and Wales in 2021 which was the highest sinch abortion became legal in 1967.. These hurdles will restrain the non-invasive prenatal testing market. Next-generation sequencing has increased the throughput, scalability, and speed, and further enables researchers to perform a wide range of applications and study biological systems at a higher level. Next-generation sequencing is a platform that has enabled the sequencing of thousands to millions of DNA molecules simultaneously. The manufacturers have introduced this technology to reduce the time and money required and optimizes the output to generate results regarding genome, and DNA testing. Major companies such as Illumina, Eurofins, Natera, Roche, and Annoroad have implemented this technology in non-invasive prenatal testing. CFDA (China Food and Drug Administration) has approved the medical instrument product registration of NGS instrument NextSeq 550AR produced by Annoroad. The non-invasive prenatal testing market is regulated by several regulations that are governed by multiple international and country-specific agencies. For instance, the US Food and Drug Administration (FDA) that issues Laboratory Developed Tests (LDTs) certification and Clinical Laboratory Improvement Amendments (CLIA) certification. The manufacturer needs to obtain a 510(k) premarket notification for in vitro diagnostic test. LDTs and CLIA certification are based on number of tests done during clinical trials. For example: For trisomy 21 (Down syndrome), there is an incidence of 1/1000. Given a target of 100 positive results, at least 100,000 samples would have to be tested to meet the requirements of a 510k. A 510k premarket notification demonstrates that the new product is at least as safe and effective as another legally-marketed device. It is mandatory for manufacturers to register a premarket notification before a new product can be certified as fit for market commercially. BioReference Laboratories, a New York-based medical laboratory company, acquired Ariosa's centralized laboratory prenatal testing business from Roche in August 2021.The acquisition will complement the current offerings of BioReference and help it improve its offerings. Ariosa Diagnostics is a US-based non-invasive prenatal screening business owned by Roche.  Major players in the non-invasive prenatal testing market are F. Hoffmann-La Roche AG, IlluminaInc., Laboratory Corporation of America Holdings, NateraInc., PerkinElmerInc., Quest Diagnostics Incorporated, Agilent TechnologiesInc., BGI Diagnosis, Berry Genomics Co., Ltd., LifeCodexx AG, Myriad GeneticsInc., NIPD Genetics, SequenomInc., Annoroad Gene Technology, Centogene AG, CounsylInc., EUROFINS Genoma Group, Eurofins Scientific, Next Biosciences, Premaitha Health PLC., Ariosa Diagnostics (Roche), Premaitha Health, Beijing Genomics Institute, Yourgene Health PLC., GE Healthcare, Koninklijke Philips N.V., Thermo Fisher ScientificInc., Pacific Biosciences of CaliforniaInc., and QIAGEN N.V. North America was the largest region in the non-invasive prenatal testing market in 2022. Western Europe was the second largest region in the global non-invasive prenatal testing market. The regions covered in the global non-invasive prenatal testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the non-invasive prenatal testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The non-invasive prenatal testing market includes revenue earned by ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, and biochemical screening tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global non-invasive prenatal testing market is segmented - 1) By Type: Consumables, Instruments 2) By End User: Hospital, Diagnostic Labs 3) By Instruments: NGS Systems, PCR Instruments, Microarrays, Ultrasound Devices, Others(Centrifuges, UV Systems, Incubators, Microscopes) 4) By Consumables: Assay Kits &Reagents, Disposables 5) By Application: Trisomy, Microdeletion, Genetics, Rh factor

Technology advisory refers to services that offer advice on developing technology strategies, technology ideation and prototyping, designing digital consulting services, and cybersecurity enhancements. Technology advisory help to create an effective IT strategy, adjust operations to meet corporate objectives, invest in the appropriate technology and implement it, adopt the shifting IT landscape, keep up with the latest technology developments, enhance enterprise architecture, manage and improve IT expenses. The main types of technology advisory services are application development, cloud services, cybersecurity and privacy, data and analytics, technology strategy and enterprise architecture, and others. Application development refers to the process of building a computer program or a series of programs to fulfil the many functions that a business requires. The different industries include banking, financial services, healthcare, IT and telecom, government, and others and involve various sizes of enterprises such as large enterprises and small and medium-sized enterprises. The technology advisory market research report is one of a series of new reports from The Business Research Company that provides technology advisory market statistics, including technology advisory industry global market size, regional shares, competitors with a technology advisory market share, detailed technology advisory market segments, market trends and opportunities, and any further data you may need to thrive in the technology advisory industry. This technology advisory market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global technology advisory market size will grow from $154.47 billion in 2022 to $161.32 billion in 2023 at a compound annual growth rate (CAGR) of 4.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global technology advisory market size is expected to grow to $184.7 billion in 2027 at a CAGR of 3.4%. The increasing requirement for simplifying business operating models and IT investment monitoring is a major driver contributing to the growth of the technology advisory market. Technology consulting firms help companies integrate technology into their business operations and create better experiences, thereby improving business processes, reducing costs, and maximizing technology-based opportunities. Technology advisory firms also help companies address cybersecurity concerns and keep data safe. For instance, Louis Vuitton uses technology consulting to create small modules in business and IT strategy and IT governance to run its operations effectively. In addition to this, companies such as Canon and Samsung have been using technology advice to optimize their operations and reduce IT costs. Technology advisory services help companies focus more on core business, access the latest technology, and minimize hardware failure, virus and spyware attacks, and database corruption. Security and reliability concerns are expected to limit the growth of the technology advisory market. Security hacks, illegal surveillance, lack of transparency, misuse of personal data, and algorithmic bias are some of the key factors that have come along with increased technological advancement. According to Verizon’s 2021 Data Breach Investigations Report, the info-tech sector is highly susceptible to external (66%) and internal (37%) threats, industrial espionage (9%), and financial motives (88%). For example, according to security tracker Firefox Monitor, Paytm Mall, a premier shopping app, experienced a major data breach that affected nearly 3.4 million customers in 2020. Organizations today rely very much on applications and IT software to conduct business. Software defects resulting in unauthorized access and the use of malicious intruders and malicious code to breach the security of the system are adding more to the security and reliability of third-party technology advisory services and hence restraining the market growth. Artificial Intelligence (AI) is a leading trend gaining traction in various business processes. AI is an amalgamation of different technologies that enables a machine to sense, understand, and act. AI helps businesses identify and solve business problems and drive measurable business value. AI helps in designing hardware infrastructure - on-premise or cloud-based, ingestion, and analysis of big data, and to enable flexibility of computing resources. For instance, in 2022, Tech Mahindra launched YANTR.AI, a cognitive artificial intelligence (AI) solution that automates and simplifies field services. With YANTR.AI, operational efficiency, productivity, and workflow control are enhanced by combining advanced analytics, artificial intelligence (AI), machine learning (ML), and optimisation with people, allowing field operations to be hyper-automated, thus increasing efficiency and customer satisfaction. With the improvement in AI technology with every passing day, it is gaining huge importance in data expertise, business processes, and workflow management. In October 2020, Accenture PLC., an Ireland-based global professional services company providing services in strategy, consulting, technology, and operations, acquired SALT Solutions AG, a German technology consultancy, for an undisclosed amount. The acquisition is expected to help Accenture plc build a cloud-based industrial internet-of-things (IoT) platform that will enable the client to reduce quality and waste issues in the whole supply chain. SALT has deep expertise in manufacturing and supply chain systems, complementing Accenture's expertise in cloud solutions and planning systems. The acquisition will help Accenture to expand its digital manufacturing and operations business in Germany. SALT Solutions AG is a German technology consultancy company implementing and maintaining IT systems for a variety of companies across different sectors. Major players in the technology advisory market are Fujitsu Ltd., HCL Technologies Limited, Booz & Co., Infosys Limited, Dell Technologies Inc., KPMG, IBM Corporation, Tata Consultancy Services Limited, Ernst & Young (EY) and McKinsey & Company. North America was the largest region in the technology advisory market in 2022. Western Europe was the second largest region in the global technology advisory market. The regions covered in the global technology advisory market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the technology advisory market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The technology advisory market consists of revenue earned by entities that provide advisory services to clients to identify, prioritize, design, and manage their investments in a various advanced technology. Technology advisory services provide consultancy on developing technology strategies, technology ideation and prototyping, design digital consulting services, and ways to enhance cybersecurity. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global technology advisory market is segmented - 1) By Service: Application development, Cloud Services, Cybersecurity and Privacy, Data and Analytics, Technology Strategy and Enterprise Architechture, Other Services 2) By End Use: Banking, Financial Services, Healthcare, IT & telecom, Government, Other End Uses 3) By Enterprise Size: Large Enterprise, Small and Medium Enterprise

Diagnostic enzymes refer to the enzymes that are employed directly or as part of an assay system to determine the presence or absence of a variety of compounds, and they are used to detect, diagnose, or predict the development of disease conditions. These enzymes are used in diagnosis because of their substrate selectivity and quantified activity when other proteins are present. The main types of products in diagnostic enzymes are carbohydrates, polymerases, nucleases, proteases, and others. Any of a class of enzymes (such as amylase) that promotes carbohydrate breakdown or synthesis is referred to as a carbohydrase (such as a disaccharide). The different sources include animals, microorganisms, and plants and are used in biocatalysts, diagnostics, pharmaceuticals, research, and biotechnology. The diagnostic enzymes market research report is one of a series of new reports from The Business Research Company that provides diagnostic enzymes market statistics, including global market size, regional shares, competitors with a diagnostic enzymes market share, detailed diagnostic enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic enzymes industry. This diagnostic enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global diagnostic enzymes market grew from $3.8 billion in 2022 to $4.02 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diagnostic enzymes market is expected to grow from $5.1 billion in 2027 at a CAGR of 6.1%. The rise in the geriatric population, which increases the patient pool for the diagnosis of chronic diseases, contributed to the growth of the diagnostic enzymes market. The proportion of people above the age of 65 increased globally, and age-related chronic ailments also increased. For example, the percentage of seniors is expected to grow from 28% in 2019 to 38% by 2050 in Japan. The increase in the ageing population has increased the patient pool of many chronic diseases such as rheumatoid arthritis, hypertension, diabetes, and cancer. People suffering from these diseases are expected to be more vulnerable to chronic diseases, thus significantly influencing market growth during this period. According to the World Population Ageing report, there were 727 million people over the age of 65 in 2020, accounting for 9.3% of the global population, and this figure is expected to rise to around 16.0% by 2050.According to the World Health Organization report for 2021, approximately 10 million cancer-related deaths occurred in 2020. Thus, the rise in the geriatric population increases the number of patients for the diagnosis of chronic diseases, which, in turn, drives the diagnostic enzymes market. The high sensitivity of enzymes to temperature and pH levels is expected to limit the diagnostic enzymes market. Enzymes need to be stored at optimum temperatures and are generally stored at -20 degrees Celsius. According to the Worthington Biochemical Corporation, variations in the reaction by one or two degrees in temperature may have a change of 10 to 20% in the result. In enzymatic reactions, this is complicated as enzymes are adversely affected by high temperatures, and are expected to be deactivated at even moderate temperatures. Enzymes are affected by changes in pH, as pH is also a factor in the stability of the enzymes. The changes in temperature and pH levels may decrease the efficiency of the diagnostic enzymes, which, in turn, hampers the growth of the diagnostic enzymes market. The use of machine learning and artificial intelligence is gradually gaining popularity in the enzyme diagnostic market. Artificial intelligence (AI) is the simulation of human intelligence in machines and is programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the enzyme diagnostic market to conduct a detailed analysis of all relevant data, provide insights into the function of enzymes, and allow physicians to understand the key determinants of the relationship between protein structure, function, and evolution, in terms of the catalysis of the reaction steps of an enzyme. For instance, companies such as BioMarker have invested in AI and machine learning for enzyme diagnostics. In June 2020, Codexis, Inc., a US-based protein engineering company and developer of high-performance enzymes, and Alphazyme LLC., a US-based company in the development and manufacture of nucleic acid metabolising enzymes, announced a co-marketing enzyme supply collaboration agreement for the production and co-marketing of enzymes for life science applications, including diagnostics. This collaboration is expected to leverage the experience and industry knowledge of Alphazyme to accelerate the market introduction of Codexis’ portfolio of high-performing life science and diagnostic enzymes while providing Alphazyme with exclusive manufacturing and co-marketing rights to CodeEvolver-improved enzymes. This partnership will allow both companies to jointly promote and sell these enzymes to innovators in life science and diagnostic markets. Major players in the diagnostic enzymes market are Genzyme, Roche, Codexis, Aldevron, Kaneka Eurogentec, Vigene Biosciences, Amano Enzymes, Advanced Enzymes Technologies, Thermo Fisher Scientific, and EKF Diagnostic. North America was the largest region in the enzymes market in 2022. The Middle East is expected to be the fastest-growing region in the global diagnostic enzyme market during the forecast period. The regions covered in the global diagnostic enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the diagnostic enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The diagnostic enzymes market consists of sales of acid phosphatase, alanine aminotransferase, cholinesterase, and aspartate aminotransferase. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global diagnostic enzyme market is segmented - 1) By Product Type: Carbohydrases, Polymerases And Nucleases, Protease, and Other Product Types 2) By Source: Animals, Microorganisms, and Plants 3) By Application: Biocatalysts, Diagnostics, Pharmaceuticals, Research, and Biotechnology

The diagnostic devices (or) equipment market consists of sales of diagnostic equipment and related services by entities (organizations, sole traders, and partnerships) that are used to identify the nature or cause of a certain phenomenon, usually related to a medical condition. Some of the devices include magnetic resonance imaging apparatuses, temperature sensors or pacemakers. The main types of diagnostic devices or equipment are x-rayed systems, ultrasound systems, computed tomography (CT) scanners, magnetic resonance imaging systems, cardiovascular monitoring and diagnostic devices, and nuclear imaging devices. X-rays refer to a type of electromagnetic radiation, just like visible light. The mobility is stationary and mobile and is used in hospitals and diagnostic imaging centers. The global diagnostic equipment market size is expected to grow from $43.81 billion in 2021 to $47.74 billion in 2022 at a compound annual growth rate (CAGR) of 9.0%. The global diagnostic equipment market size is expected to grow to $59.46 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. An increase in the geriatric population is expected to propel the growth of the diagnostic devices market going forward. Older people are likely to suffer from diseases such as diabetes, cancer, and arthritis, among others, which would increase the demand for diagnostic devices. For instance, in 2020, according to the United Nations, a US-based intergovernmental organization, there are approximately 727 million persons are aged 65 years and above worldwide, and expected to reach approximately 1.5 billion persons by 2050. Therefore, the increase in the geriatric population is driving the growth of the diagnostic devices market.  The emergence of routine diagnostic kits is a key trend gaining popularity in the diagnostic devices market. Companies operating in the market are focusing on developing diagnostic kits to gain market coverage. For instance, in March 2022, Mylab Discovery Solutions, an India-based healthcare company, is set to launch an entire range of routine diagnostic kits and devices in conventional and point-of-care formats. Immunology, Biochemistry, and Haematology are the three main market sub-segments represented by the devices and kits included in them.  In July 2021, DiaSorin S.p.A., an Italy-based biotechnology company, acquired Luminex Corporation for a deal amount of $1.8 billion. Through the acquisition, DiaSorin would gain access to Luminex’s multiplexing technology and a portfolio that would strengthen its existing offering while expanding the group's presence in the United States. Further, this agreement would give the life science sector access to Luminex's applications, promoting academic and scientific research, improving collaboration with biopharma businesses, and boosting access to clinical multiplexing assays for upcoming Value-Based Care initiatives. Luminex Corporation is a US-based biotechnology company that manufactures medical diagnostic devices. Major players in the diagnostic equipment market include Philips Healthcare, Hitachi Medical Systems, Fujifilm Holdings, Siemens Healthcare, and GE Healthcare. The regions covered in global diagnostic equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the diagnostic devices or equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global diagnostic equipment market is segmented - 1) By Type: X-Ray Systems, Ultrasound Systems, Computed Tomography (CT) Scanners, Magnetic Resonance Imaging Systems, Cardiovascular Monitoring and Diagnostic Devices, and Nuclear Imaging Device 2) By Mobility: Stationary, Mobile 3) By End User: Hospitals, Diagnostic imaging centres

Testing, inspection, and certification refer to a conformity analysis for operational efficacy; they catalyse research and development and innovation in new fields through verification and validation; and they establish mutual recognition to ease market access and assure the safety, integrity, and quality of goods and services through conformity evaluation and assurance in various industries. The main types of services provided in testing, inspection, and certification market are testing service, inspection service and certification service. The testing service is a method of determining the presence, quality, or validity of product or goods. Testing, inspection, and certification services can sourced in-house or outsourced and are used for applications such as quality and safety, production evaluation, industrial inspection and system certification. These services are mostly used by industries such as consumer goods and retail, food and agriculture, oil and gas, construction and engineering, energy and chemicals, manufacturing, transportation, industrial and automotive and others. The testing, inspection, and certification market research report is one of a series of new reports from The Business Research Company that provides testing, inspection, and certification market statistics, including testing, inspection, and certification industry global market size, regional shares, competitors with an testing, inspection, and certification market share, detailed testing, inspection, and certification market segments, market trends and opportunities, and any further data you may need to thrive in the testing, inspection, and certification industry. This testing, inspection, and certification market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global testing, inspection, and certification market size grew from $223.54 billion in 2022 to $232.8 billion in 2023 at a compound annual growth rate (CAGR) of 4.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The testing, inspection, and certification market size is expected to grow to $275.16 billion in 2027 at a CAGR of 4.3%. The strict regulatory standards imposed by governments to ensure product safety and environmental protection are expected to propel the growth of the testing, inspection, and certification market. The increased risk to human life and the influence on the environment are the main worries, prompting customers to seek dependable and high-quality products. Safety testing, inspection, and certification services are being implemented by many organizations worldwide to resolve product safety and quality problems by following legislative rules. According to the Europe Commission's CO2 emission performance standards for cars and vans in January 2020, regulation (EU), 2019/631 was enforced to set performance standards for new passenger vehicles to decrease the average CO2 emission. Therefore the strict regulatory standards imposed by governments will drive the testing, inspection, and certification market. The advent of new technologies in testing, inspection, and certification products and services is a key trend booming the testing, inspection, and certification market. Artificial intelligence is changing corporate operations in practically every sector, including testing, inspection, and certification. Automated inspection is used to satisfy the demands of physically challenging inspection zones. In November 2020, Shanghai introduced the world's first automated laboratory for testing, inspection, and certification, marking a significant milestone for the city to become a global scientific innovation center. The lab uses robotic arms, autonomous guided vehicles, artificial intelligence, and deep learning models to replace the traditional testing and certification procedure, entirely dependent on manual operations. In September 2021, Intertek Group plc, an England-based company offering assurance, inspection, product testing, and certification, acquired SAI Global Assurance, for an undisclosed amount. The acquisition aims to strengthen their combined assurance offering by providing increased scale and geographic coverage in delivering additional risk-based quality audit, inspection, training, and certification services and enhanced global market access capabilities through our standards service offering. SAI Global, a US-based company, offers risk management services, quality assurance audit and certification, auditor training, standards information services, and property service. Major players in the testing, inspection, and certification market are SGS Group, Bureau Veritas, Intertek, Element Materials Technology, TÜV SÜD, Eurofins Scientific, TÜV Rheinland, DEKRA SE, DNV GL, Applus+, ALS Limited, TÜV NORD, IRClass, ASTM, TIC Sera, Hohenstein, BSI Group, SAI Global and AsureQuality. Asia-Pacific was the largest region in the testing, inspection and certification market in 2022. The regions covered in the testing, inspection and certification market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the testing, inspection and certification market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The testing, inspection, and certification market includes revenues earned by entities by providing conformity assessment services for good practices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global testing inspection and certification market is segmented - 1) By Service Type: Testing Service, Inspection Service, Certification Service 2) By Sourcing Type: In-House, Outsourced 3) By Application: Quality And Safety, Production Evaluation, Industrial Inspection, System Certification 4) By End-User: Consumer Goods And Retail, Food And Agriculture, Oil And Gas, Construction And Engineering, Energy And Chemicals, Manufacturing, Transportation, Industrial And Automotive, Other End-Users

Genetic testing refers to a sort of medical examination that looks for alterations in genes, proteins, or chromosomes. A genetic test's results can identify a genetic ailment, as well as determine a person's risk of developing a genetic disorder. Genetic testing is used to confirm specific genetic disorders in children and their conditions based on physical signs and symptoms. The main types of genetic testing are predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, nutrigenomic testing, and other types. The predictive tests are part of a new and rapidly expanding class of medical tests that are fundamentally different from traditional medical diagnostic examinations. The various technologies involved are cytogenetic testing, biochemical testing, and molecular testing and are used for different diseases such as Alzheimer's disease, cancer, cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy, thalassemia, Huntington's disease, rare diseases, and other diseases. It is used in several applications, such as cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. The genetic testing market research report is one of a series of new reports from The Business Research Company that provides genetic testing market statistics, including global market size, regional shares, competitors with a genetic testing market share, detailed genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the genetic testing industry. This genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global genetic testing market size grew from $15.42 billion in 2022 to $17.23 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The genetic testing market size is expected to grow to $26.21 billion in 2027 at a CAGR of 11.1%. The rising prevalence of genetic disorders is expected to propel the growth of the genetic testing market going forward. Genetic disorders refer to some diseases that cause symptoms at birth, while others develop over time. Genetic testing can help get a diagnosis for a genetic issue and information about the chances of developing cancer. For instance, in November 2021, according to the National Center for Biotechnology Information, a US-based medical organization, genetic illnesses were found in 9.4% of pediatric patients, with 44.7% of these patients being critically ill newborns. Also, 13.17 million patients were suffering from unique genetic disorders in the US. Therefore, the rising prevalence of genetic disorders is driving the genetic testing market. Technological advancement is a crucial trend gaining popularity in the genetic testing market. Major companies operating in the genetic testing market are focused on developing technology to sustain their position in the market. For instance, in December 2020, Cell ID Pte. Ltd., a Singapore-based company that manufactures, genetic testing products launched a portable genetic test for COVID-19 named Quiz PCR Biochip. This is a portable palm-sized moveable genetic test kit that utilizes an app to confirm if a person has COVID-19. This device also had a QR code for tracking. This device works on pooled screening technology. This can be easily moveable and can take tests anywhere at any time. In January 2022, Exact Sciences, a US-based molecular diagnostics company that manufactures genetic testing products acquired Prevention Genetics for a deal amount of $190 million. As a result of this acquisition, Exact Sciences aims to increase hereditary cancer testing for more patients. Prevention Genetics is a US-based company that manufactures clinical DNA (genetic) tests for genetic germline (inherited) illnesses. Major players in the genetic testing market are Abbott Laboratories, Bio-Rad Laboratories Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Illumina Inc., Myriad Genetics Inc., QIAGEN, Thermo Fisher Scientific, Quest Diagnostics, BGI Group, Biocartis Group, 23 and Me Inc., Blueprint Genetics, CSL Limited, bioMerieux SA, PerkinElmer Inc., and Agilent Technologies Inc. North America was the largest region in the genetic testing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The genetic testing market includes revenues earned by entities by chromosomal genetic tests, molecular genetic tests (or gene tests), biochemical tests, newborn screening, and diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global genetic testing market is segmented - 1) By Type: Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Nutrigenomic Testing, Other Types 2) By Technology: Cytogenetic Testing, Biochemical Testing, Molecular Testing 3) By Disease: Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Other Diseases 4) By Application: Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Other Applications

Epigenetics is a change in gene activity transmitted to younger cells without modifying the DNA sequence. Epigenetic processes are natural and necessary for many organisms to work, but unusual occurrences can cause disorders, such as various types of cancer, reproductive illnesses, and cardiovascular illnesses. Epigenetics is used detect a type of cancers earlier. The main products used in epigenetics market are reagents, enzymes, instruments and kits. Reagents are compounds or substances that are used for chemical analysis or epigenetic testing. DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification and chromatin structures are the technologies used in epigenetics. The application included oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases and other applications. These epigenetics are used by academic and research institutes, pharmaceutical, and biotechnology companies, contract research organizations and other end users. The epigenetics market research report is one of a series of new reports from The Business Research Company that provides epigenetics market statistics, including epigenetics industry global market size, regional shares, competitors with an epigenetics market share, detailed epigenetics market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetics industry. This epigenetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global epigenetics market size grew from $7.38 billion in 2022 to $8.85 billion in 2023 at a compound annual growth rate (CAGR) of 20.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The epigenetics market size is expected to grow to $18.21 billion in 2027 at a CAGR of 19.8%. The growing prevalence of cancer and other diseases is significantly driving the growth of the epigenetics market. The rising prevalence of diseases increases the demand for epigenetics. According to the European Commission's Joint Research Centre from Ispra, the number of new cancer cases in the European Union (EU) and European Free Trade Association (EFTA) countries will rise by 21.4%, from 2.8 million in 2020 to 3.4 million in 2040. Furthermore, according to the Centers for Disease Control and Prevention (CDC), approximately 659,000 people in the United States die of heart disease each year. The increasing prevalence of cancer and other diseases requires testing and knowing the modifications that happened in the genes, which will invariably increase the usage and demand of epigenetics. Thus, the growing prevalence of cancer and other diseases drives the epigenetics market in the coming years. Technological advancement is the key trend in the epigenetics market. The key players in the epigenetics sector are focusing on developing various technologically advanced products and services to strengthen their position in the market. For instance, in May 2021, Givaudan Active Beauty, a Switzerland-based company specialising in fragrance, beauty, taste and wellbeing, launched Chronoglow. Chronoglow is a skin-care-beneficial active component created by green fractionation and supported by artificial intelligence (AI) that can replicate natural epigenetic mechanisms. Chronoglow is a natural skin remedy made from Haberlea rhodopensis, often known as the resurrection plant, which can improve the skin's luminosity and reverse the signs of aging. In December 2020, Exact Sciences, a US-based molecular diagnostic company, acquired Base Genomics for $140 million. As a result of this acquisition, Exact Sciences aims to create a multi-cancer early detection blood test. This acquisition also aids in the acceleration of clinical and commercial development. Base Genomics is a UK-based epigenetics company working on designing a blood test for minimal residual disease and early-stage cancer. Major players in the epigenetics market are Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Bio-Rad, New England Biolabs, Agilent, Qiagen, Zymo Research, Perkinelmer, Diagenode, Hoffmann-La Roche Ltd., Eisai Co Ltd and Novartis AG. North America was the largest region in the epigenetics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epigenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The epigenetics market includes revenues earned by entities methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global epigenetics market is segmented - 1) By Product: Reagents, Enzymes, Instruments, Kits 2) By Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification, Chromatin Structures 3) By Application: Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications 4) By End-User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organisations, Other End Users

Gene editing is a technology that allows genetic material to change genetic code at a particular location in a genome. It involves cell line engineering, animal genetic engineering, and plant genetic engineering. The main technology types of gene editing are CRISPR, TALEN, and ZFN. CRISPR is a novel technology that allows geneticists and medical researchers to edit parts of the genome by removing, inserting, or modifying DNA sequences. The various applications include biotechnology, pharmaceuticals, and contract research organization that are used in animal genetic engineering, plant genetic engineering, and cell line engineering. The gene editing market research report is one of a series of new reports from The Business Research Company that provides gene editing market statistics, including gene editing industry global market size, regional shares, competitors with a gene editing market share, detailed gene editing market segments, market trends and opportunities, and any further data you may need to thrive in the gene editing industry. This gene editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global gene editing market will grow from $6.35 billion in 2022 to $7.44 billion in 2023 at a compound annual growth rate (CAGR) of 17.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global gene editing market is expected to grow to $14.28 billion in 2027 at a CAGR of 17.7%. The rising infectious diseases act as one of the major drivers of the gene editing market. Gene editing techniques are used for the detection of infectious diseases such as HIV. Infectious diseases are caused by microorganisms like bacteria, viruses, fungi, and parasites. Gene therapy treats infectious diseases by blocking the replication of the infectious agent that causes the disease at the extracellular level. Gene editing introduces new genetic material into the cells of living organisms with the intention of treating diseases. Infectious diseases are constantly on the rise. For instance, according to the World Health Organization (WHO), infectious diseases kill more than 17 million people per year. In addition to that, according to the AP-NORC (a research initiative by the Associated Press and the University of Chicago) survey, out of 1,067 adults in the US surveyed, 71% are in favor of gene editing for the treatment of incurable, hereditary diseases such as Huntington’s disease and 67% of Americans support the use of gene editing to prevent diseases such as cancer. Ethical issues in general public with respect to gene editing is one of the major restraining factors for the market. Many researchers and ethicist have argued against gene editing due to different reasons such as off-target effect (edits in the wrong place), mosaicism (when only some of the cells carry the edits) and safety concerns. Some even argued that gene editing will lead to the creation of classes of individuals who will be genetically modified to be able to do things that a normal human being is not supposed to do according to the laws of nature. Due to these reasons, gene editing is still not considered to be safe and effective by many nations and international organizations. For instance, in 2020, as per the article published in TIME, scientists from Canada, China, France, Germany, Italy, New Zealand, and the USA have proposed a temporary prohibition on research on gene editing on human eggs, embryos, and sperms. Gene editing (also called genome editing) is a group of technologies that allow the researchers to change an organism's DNA by adding, removing or altering genetic material at particular locations in the genome. The emergence of advanced genome editing techniques is one of the major trends in the gene editing market. The new techniques in genome editing are relatively inexpensive and can be used in a variety of application areas such as improving the food supply in agriculture, rectifying specific genetic mutations in the human genome and preventing the spread of diseases. For instance, CRISPR-Cas9 is a gene editing technique and stands for Clustered Regularly Interspace Short Palindromic Repeats. The technique uses a strand of DNA as molecular scissors used to make cuts in DNA at specific points to make space to add new genomes. This technique is faster, cheaper, more accurate and efficient than other existing genome editing methods. Companies investing in CRISPR technology are Crispr therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas medicine. European regulatory framework divided gene therapy into two categories, germline gene therapy, and somatic gene therapy. In germ line gene therapy, modified genes will be passed on to next generations whereas it’s not the same case with somatic gene therapy. Current regulation by the EU has only allowed somatic gene therapy, therefore, germline gene therapy is banned. The European Medical Association provides guidelines on gene therapy for preparing market authorization application to obtain approval from the authority to carry on research and development activities in gene therapy. For instance, the EU provides guidance note on gene therapy medicinal product which is intended for use in humans, defines scientific principles and provide guidance for development and evaluation of gene therapy products. In December 2020, AnGes MG, Inc., a Japan-based biopharmaceutical company that offers nucleic acid drugs for patients with asthma, allergy, and rheumatism, acquired Emendo Bio, Inc. for $250 million.This acquisition will expand AnGes MG, Inc.'s pipeline and partnerships and introduce gene editing capabilities. Emendo Bio, Inc., a USA-based company that develops next generation gene editing tools for genetic disorders, addresses the current technological gaps for realizing the promise of gene therapy. Major players in the gene editing market are CRISPR, GenScript USA Inc., Horizon Discovery Group PLC., Integrated DNA Technologies, New England Biolabs, OriGene Technologies, Thermo Fisher Scientific, Merck KgaA, GenScript Corporation, Editas Medicine, Lonza Group, Sangamo, DNA 2.0, Bio RAD, Allele, Addgene, Sigma-Aldrich Corporation, Transposagen Biopharmaceuticals, Recombinetics, Precision Biosciences, Promega, Juno Therapeutics, Intellia Therapeutics, Qiagen, GE Healthcare Lonza, Cellectis, Dharmacon, AstraZeneca, and Agilent Technologies. North America was the largest region in the gene editing market in 2022. Western Europe was the second largest region in the global gene editing market. The regions covered in the global gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The gene editing market includes revenue earned by zinc-finger nucleases (ZFNs) and homing endonucleases or meganucleases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global gene editing market is segmented - 1) By Technology: CRISPR, TALEN, ZFN 2) By End Users: Biotechnology, Pharmaceutical, Contract Research Organization 3) By Application: Animal Genetic Engineering, Plant Genetic Engineering, Cell Line Engineering